Residual solvent determination by head space gas chromatography with flame ionization detector in omeprazole API

ARTICLE

Residual solvent determination by head space gas chromatography with flame ionization detector in omeprazole API

Saurabh Pandey^I,*; Preeti Pandey^I; Raj Kumar^II; Narendra Pal Singh^III

^IPranveer Singh Institute of Technology, Kanpur, India

^IIK.H.B College of Pharmacy, Jaunpur, India

^IIIInstitute of Pharmacy, V.B.S Purvanchal University, Jaunpur, India

ABSTRACT

Residual solvents in pharmaceutical samples are monitored using gas chromatography with head space. Based on good manufacturing practices, measuring residual solvents is mandatory for the release testing of all active pharmaceutical ingredients (API). The analysis of residual organic solvents (methanol, acetone, cyclohexane, dichloromethane, toluene) in Omeprazole, an active pharmaceutical ingredient was investigated. Omeprazole is a potent reversible inhibitor of the gastric proton pump H+/K+-ATPase. The Head space gas chromatography (HSGC) method described in this investigation utilized a SPB^TM-624, Supelco, 30 m long x 0.25 mm internal diameter, 1.4µm-thick column. Since Omeprazole is a thermally labile compound, the selection of the proper injector temperature is critical to the success of the analysis. The injector temperature was set at 170ºC to prevent degradation. The initial oven temperature was set at 40ºC for 12 min and programmed at a rate of 10ºC min^-1 to a final temperature of 220ºC for 5 min. Nitrogen was used as a carrier gas. The sample solvent selected was N,N-dimethylacetamide. The method was validated to be specific, linear, precise, sensitive, rugged and showed excellent recovery.

Uniterms: Headspace-gas chromatography. Omeprazole. Method validation. Residual solvents release testing.

RESUMO

Solventes residuais em amostras farmacêuticas são monitoradas utilizando-se cromatografia a gás "headspace". Com base nas boas práticas de fabricação, a medida de solventes residuais é obrigatória para o teste de liberação de todos os ingredientes farmacêuticos (API). Efetuou-se a análise de solventes orgânicos residuais (metanol, acetona, cicloexano, diclorometano, tolueno) em omeprazol, ingrediente farmacêutico ativo. O omeprazol é potente inibidor reversível da bomba de prótons H+/K+-ATPase. A cromatografia a gás "headspace" (HSGC) descrita nessa pesquisa utilizou um SPB^TM-624, Supelco, de 30 m de comprimento x 0,25 mm de diâmetro interno, e coluna de 1,4 µm de espessura. Considerando-se que o omeprazol é termicamente lábil, a seleção da temperatura apropriada do injetor é crítica para impedir a degradação. A temperatura inicial do forno foi de 40 ºC, por 12 minutos, e programada à taxa de acréscimo de 10 ºC min^-1 até a temperatura final de 220 ºC, por 5 minutos. Nitrogênio foi utilizado como gás de transporte. Selecionou-se como solvente a N,N-dimetilacetamida. O método foi validado mostrando-se específico, linear, preciso, sensível, robusto e com excelente recuperação.

Unitermos: Cromatografia a gás "headspace". Omeprazol. Método de validação. Teste de liberação de solventes residuais.

INTRODUCTION

Organic solvents are routinely applied during synthesis of drug substances, excipients, or during drug product formulation. They are not desirable in the final product, mainly because of their toxicity, influence on the quality of crystals of the drug substance, and their odor or taste, which can be unpleasant for patients. To remove them, various manufacturing processes or techniques (usually under increased temperature or/and decreased pressure) are in use. Even after such processes, some solvents still remain, albeit in small quantities. These small quantities of organic solvents are commonly known as organic volatile impurities (OVIs) or residual solvents (RS). The determination of residual solvents in drug substances, excipients or drug products is known to be one of the most difficult and demanding analytical tasks in the pharmaceutical industry. Furthermore, the determination of polar residual solvents in pharmaceutical preparations continues to present an analytical challenge mainly because these compounds are difficult to remove from water or polar solvents (ICH, 2002, 1997; Hymer, 2003). The manufacturing of active pharmaceutical ingredients (API) under GMP (good manufacturing practice) conditions requires adequate control of the quality of the different ingredients involved in the synthesis. Organic residual solvents must therefore be controlled, and their purity determined, before any GMP synthesis.

Inadequate attention has been paid during pharmaceutical investigations. Headspace gas chromatography (HSGC) is a technique where the liquid or solid sample is set in a closed vessel until the volatile components reach equilibrium between the sample and the gas volume above, i.e., the so called "headspace". An aliquot of the headspace is sampled and introduced into a gas chromatographic (GC) column for analysis. Regulatory agencies and pharmacopoeias suggest headspace gas chromatography as the most suitable technique for residual solvent testing for active substances and formulations soluble in water. Residual solvent specification limits, set in accordance with the toxicity of solvents, vary from a few ppm to thousands of ppm. HSGC determination of residual solvents is nowadays a mature technique (Grodowska et al., 2010; Puranik et al., 2009; Groman et al., 2008; Alzaga, 2007; Camarasu, 2006; Michulec et al. 2005; Rocheleau et al., 2004; Klick, 2004; Snow, 2002; Hymer et al., 2003; Iofer et al., 1984).

Direct injection of analytes evaporated through equilibration between liquid (or solid) phase and gas phase into a GC system minimized the contamination of the GC system and the deterioration of the GC column (Kolb et al.,1997). In addition, the automation of equilibrium and injection procedure reduced analysis time and improved reproducibility in the injection procedure.

Omeprazole is a potent reversible inhibitor of the gastric proton pump H+/K+-ATPase. The molecular structure of omeprazole is illustrated in Figure 1.

It is composed of a substituted pyridine ring linked to a benzimidazole by a sulfoxide chain. Chemically designed as 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole. Omeprazole is a white powder, slightly soluble in water, but is highly soluble in alkaline solutions as the negatively charged ion. It is an ampholyte with pKa=4 (pirydinium ion) and 8.8 (benzimidazole). In solution, Omeprazole degrades rapidly at low pH values, and it is photo and heat sensitive (Sarisuta et al., 1997). Its molecular formula and weight is C₁₇H₁₉N₃O₃S, and 345.4, respectively (Marzocchi et al., 2001). Omeprazole is known for its high potential to interact with other drugs (United States Pharmacopoeia, 2006; Anderson, 1996; Mayer,1996). The aim of this study was to develop a HSGC method for analysis of residual solvents in omeprazole API. The residual solvents were compared to standard solvents and the ICH standard residual solvents limit.

EXPERIMENTAL

Material

Used Chemicals were obtained from the following suppliers: methanol (sigma-aldrich, Mumbai, India), acetone, cyclohexane, dichloromethane (DCM) and toluene (Qualigens, Mumbai, India) N,N-dimethylacetamide (DMA) HPLC grade (Spectrochem, Mumbai, India). Omeprazole API was obtained from Shipra Pharma, Mumbai, India.

Instrumentation

A Gas chromatograph (Agilent technologies 6890N) equipped with a flame ionization detector, a Headspace sampler (Agilent technologies G1888) was used to load the sample. An analytical balance (XS 205 from Mettler Toledo) and autopippette (100 - 1000 µL from Eppendorf) were used. The headspace injector and GC conditions are provided in Table I.

Chromatographic conditions

A volume of 1ml standard and sample solution was injected into the GC injection port. The temperature of the injection port was maintained at 170 ºC at a split ratio of 1:10, with nitrogen as a carrier gas. The pressure was maintained at 14 psi with flow of 1 mL min^-1. The temperature of the detector was set at 250 ºC. Temperature gradient was maintained at 40 ºC for twelve min and then increased at a rate of 10 ºC min^-1 up to 220 ºC to a final temperature of 220 ºC and maintained for 5 min.

Preparation of standard and sample vial

DMA was selected as the standard and sample diluent because of its ability to dissolve a wide variety of substances. It has a high boiling point that does not interfere with more volatile solvents, analyzed by GC. A common standard stock solution in DMA containing all the known residual solvents of Omeprazole API (i.e., methanol, acetone, cyclohexane, dichloromethane and toluene) was prepared in such a way that it had a final concentration of 3000 ppm for methanol, 5000 ppm for acetone, 100 ppm for dichloromethane, 890 ppm for toluene and 3880 ppm for cyclohexane.

The standard vial was prepared with 1 mL of the standard solution and the sample vials were prepared with approximately 120 mg of sample with 1 mL DMA as diluent.

Method validation

The method validation was done by evaluating specificity, limit of detection (LOD) and limit of quantitation (LOQ), linearity, accuracy, repeatability, ruggedness, system suitability and method precision of residual solvents as indicated in the ICH harmonised tripartite guideline (1997, 2002).

RESULT AND DISCUSSION

Specificity

The omeprazole API sample was spiked with dichloromethane, toluene, methanol, cyclohexane and acetone individually, and each sample was chromatographed to examine interference, if any, of the residual solvent peaks with each other. The retention time for standard methanol, acetone, dichloromethane, cyclohexane and toluene was found to be 3.41, 5.23, 6.24, 12.14 and 18.26 min, respectively. A typical chromatogram of standard solution is shown in Figure 2.

Linearity

The linearity of the method was determined by making injections of each residual solvent over the range 15-150% LOQ. Three replicates were performed at each level. The calibration curves were obtained with the average of peak area ratios of three replicates. The correlation coefficient (r²) values for all residual solvents were found to be higher than 0.997 and the calibration curves were linear within the range. Table II shows the linearity values for the residual solvents.

Limit of Detection (LOD) and Quantitation (LOQ)

The LOD and LOQ were calculated by instrumental and statistical methods. For the instrumental method, LOD is determined as the lowest amount to detect, and LOQ is the lowest amount to quantify, by the detector. The LODs of residual solvents in Omeprazole API were determined based on a signal-to-noise ratio of 3:1. The LOQs of residual solvents were determined based on a signal-to-noise of ratio 10:1. The values for the LOD and LOQ for dichloromethane, toluene, methanol, cyclohexane and acetone are shown in Table II.

Accuracy (recovery)

A known amount of sample (120 mg) was taken separately in five different vials and spiked with known quantities of DCM, toluene, methanol, cyclohexane and acetone at three different levels (50, 100 & 150 % of Quantization Limit) in triplicate. The results are presented in Table III. From accuracy data, the % recovery of residual solvents was found within the limits (80-120%) and % RSD for area did not exceed 10.0 for each solvent as per the ICH guideline. Results indicate that the method has an acceptable level of accuracy.

Precision

For the system precision, a single injection of blank and six replicate injections of standard solution were observed. Intermediate precision study was carried out by a different analyst, on a different instrument and on another day. Table IV shows the results for intermediate precision. The % RSD for each solvent was found to be less than 10 and system suitability was passed.

Robustness

To demonstrate the robustness of the method, the system suitability criteria with slight variations in method parameters, was verified. The following parameters were changed: column oven temperature ± 5 ºC from the ideal conditions (initial column oven temperature at 35 ºC and 45 ºC), the flow rate ± 10% from the ideal conditions (flow rate 0.9 mL/min and 1.1 mL/min), the split ratio ± 10% from the ideal conditions (the split ratio of 1:9 and 1:11), two columns of different serial numbers. The results are shown in Table V. For the robustness study, individual %RSD should not exceed 10.0 and cumulative (overall) % RSD should not exceed 15.0, for each component, and system suitability should pass.

System suitability

The system suitability criterion was taken to be the resolution between the critical pairs, i.e., acetone and dichloromethane. The system suitability was evaluated by injecting the standard solution on various days before starting any exercise during the validation study. The criterion for system suitability was that the resolution between the above-mentioned critical pair should not be less than 1.5 and it was found to be well above the minimum passing limit (Table VI).

CONCLUSION

A single, rapid and highly selective HSGC method was developed and validated for the quantification of residual solvents present in Omeprazole API through an understanding of the synthetic process, nature of solvents and nature of stationary phases of columns. The residual solvents methanol, acetone, cyclohexane, dichloromethane and toluene were determined. The developed method is specific, accurate, precise and rugged as per ICH guidelines.

Received for publication on 16^th July 2010

Accepted for publication on 28^th February 2011

• ALZAGA, R.; RYAN, R.W.; TAYLOR-WORTH, K.; LIPCZYNSKI, A.M.; SANDRA, P.J. A generic approach for the determination of residues of alkylating agents in active pharmaceutical ingredients by in situ derivatization-headspace-gas chromatography-mass spectrometry. J. Pharm. Biomed. Anal., v.45, n.3, p.472-479, 2007.
• ANDERSSON, T. Pharmacokinetics, metabolism & interactions of acid pump inhibitors: focus on omeprazole, lansoprazole, pantoprazole, Clin. Pharmacokinet., v.31, n.1, p.9-28, 1996.
• CAMARASU, C.; MADICHIE, C.; WILLIAMS, R. Recent progress in the determination of volatile impurities, Trends Anal. Chem, v.25, n.8, p.768-777, 2006.
• GRODOWSKA, K.; PARCZEWSKI, A. Analytical methods for residual solvents determination in pharmaceutical products. Acta Pol. Pharm. Drug Res., v.67, n.1, p.13-26, 2010.
• GROMAN, A.; KAMIE, A. Validation of an analytical procedure ñ control of residual solvents in pharmaceutical substance. Acta Pol. Pharm. Drug Res., v.65, n.6, p.783-787, 2008.
• HYMER, C.B. Residual solvent testing: a review of gas-chromatographic and alternative techniques. Pharm. Res, v.20, n.3, p.337-344, 2003.
• INTERNATIONAL CONFERENCE OF HARMONIZATION. Impurities: Guideline for residual solvents. ICH harmonised tripartite guideline, 1997. Available at: <http://www.ich.org>. Accessed on: 09 jan. 2008.
• INTERNATIONAL CONFERENCE ON HARMONIZATION. Impurities: Guideline for Residual Solvents (Maintenance), 2002. Available at: <http://www.ich,org>. Accessed on: 09 jan. 2008.
• IOFEE, B.V.; VITENBERG, A.G. Head-Space analysis and related methods in gas chromatography New York: John Wiley & Sons, 1984. p.23-24.
• KLICK, S.; SKOLD, A. Validation of a generic analytical procedure for determination of residual solvents in drug substances. J. Pharm. Biomed. Anal, v.36, n.2, p.401-409, 2004.
• KOLB, B.; ETTRE, L. S. Static headspace-gas chromatography: theory and practice. New York: Wiley-VCH, 1997. p.3-4.
• MARZOCCHI, L.; MOYANO, J.R.; ROSSI, A.; MUNOZ, P.; ARIAS, M.J.; GIORDANO, F. Current status of ATP-ase proton pump inhibitor complexation with cyclodextrins. Biog. J. Armenia, v.53, special issue, p.176-193, 2001.
• MAYER, U.A. Interactions of proton pump inhibitiors with cytochromes p450, consequences for drug interactions. Yale J. Biol. Med, v.69, n.3, p.203-209, 1996.
• MICHULEC, M.; WARDENCKI, W. Development of headspace solid-phase microextraction-gas chromatography method for the determination of solvent residues in edible oils and pharmaceuticals. J. Chromatogr. A, v.1071, n.1-2, p.119-124, 2005.
• PURANIK, S.B.; PAWAR, V.; LALITHA, N.; PAI, P.N.S.; RAO, G.K. Residual solvent analysis in hydrochloride salts of active pharmaceutical ingredients. Pak. J. Pharm. Sci, v.22, n.4, p.410-414, 2009.
• ROCHELEAU, M.J.; TITLEY, M.; BOLDUC, J. Measuring residual solvents in pharmaceutical samples using fast gas chromatography techniques J. Chromatogr. B, v.805, n.1, p.77-86, 2004.
• SARISUTA, N.; TOURTIP, T.; CHUARCHAROERN, S. Chemical stability and mechanism of degradation of omeprazole. Thai. J. Pharm. Sci., v.22, n.2, p.81-88,1998.
• SNOW N.H.; SLACK G.C. Head-space analysis in modern gas chromatography. Trends Anal. Chem , v.21, n.9-10, p.608-617, 2002.
• UNITED STATES PHARMACOPOEIA. Rockville: United States Pharmacopoeia Convention, 2006. p.1577-1578.

Publication Dates

• Publication in this collection
  05 Aug 2011
• Date of issue
  June 2011

History

• Accepted
  28 Feb 2011
• Received
  16 July 2010